Cellectis S.A [ALCLS] vs Inventiva S.A [IVA] Detailed Stock Comparison

Cellectis S.A

Euronext
Loading...

Inventiva S.A

Euronext
Loading...

TLDR: Quick Comparison Summary

Based on 18 vital metrics comparison: Cellectis S.A wins in 8 metrics, Inventiva S.A wins in 9 metrics, with 0 ties. Inventiva S.A appears stronger overall.

View Metrics Details

Vital Metrics Comparison

MetricCellectis S.AInventiva S.ABetter
P/E Ratio (TTM)-7.41-1.63Cellectis S.A
Price-to-Book Ratio2.26-21.80Inventiva S.A
Debt-to-Equity Ratio93.67-14.91Inventiva S.A
PEG Ratio-3.38-3.81Inventiva S.A
EV/EBITDA-7.60-7.87Inventiva S.A
Profit Margin (TTM)-93.00%0.00%Inventiva S.A
Operating Margin (TTM)-52.69%-991.89%Cellectis S.A
Return on Equity-48.02%172.73%Inventiva S.A
Return on Assets (TTM)-7.43%-56.77%Cellectis S.A
Free Cash Flow (TTM)$16.31M$-86.26MCellectis S.A
1-Year Return59.89%207.93%Inventiva S.A
Price-to-Sales Ratio (TTM)4.8143.76Cellectis S.A
Enterprise Value$213.85M$753.35MInventiva S.A
EV/Revenue Ratio3.9644.39Cellectis S.A
Gross Profit Margin (TTM)85.50%N/AN/A
Revenue per Share (TTM)$1$0Cellectis S.A
Earnings per Share (Diluted)$-0.50$-3.76Cellectis S.A
Beta (Stock Volatility)3.070.75Inventiva S.A
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends

Cellectis S.A vs Inventiva S.A Stock Performance Analysis

Loading Price Chart...

Cellectis S.A
Inventiva S.A
Cellectis S.A Stock Overview | Inventiva S.A Stock Overview

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Cellectis S.A-1.48%31.72%23.55%118.25%166.96%73.84%
Inventiva S.A-5.43%2.23%12.47%91.29%85.66%139.34%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Cellectis S.A59.89%14.56%-81.29%-87.42%-50.00%-50.00%
Inventiva S.A207.93%-15.13%-58.13%-39.08%-39.08%-39.08%

News Based Sentiment: Cellectis S.A vs Inventiva S.A

Cellectis S.A

News based Sentiment: MIXED

Cellectis experienced a month of both positive and negative developments. While the AstraZeneca partnership and promising gene therapy data are encouraging, the Q2 earnings miss and 'Neutral' analyst rating highlight ongoing challenges. This creates a mixed investment picture, making it a significant but not game-changing month for the company.

View Cellectis S.A News Sentiment Analysis

Inventiva S.A

News based Sentiment: POSITIVE

October proved to be a pivotal month for Inventiva, highlighted by a strategic CEO appointment geared towards U.S. commercialization and a notable surge in stock price fueled by positive analyst ratings and increased institutional investment. These factors collectively suggest a strengthening investment narrative.

View Inventiva S.A News Sentiment Analysis

Performance & Financial Health Analysis: Cellectis S.A vs Inventiva S.A

MetricALCLSIVA
Market Information
Market Cap i€304.99M€742.58M
Market Cap CategoryMid capMid cap
10 Day Avg. Volume i836,406405,098
90 Day Avg. Volume i468,991343,746
Last Close€2.99€5.05
52 Week Range€1.01 - €3.41€1.43 - €5.55
% from 52W High-12.30%-9.01%
All-Time High€41.95 (Nov 02, 2015)€16.30 (Jan 18, 2021)
% from All-Time High-92.87%-69.02%
Growth Metrics
Quarterly Revenue Growth0.91%1.05%
Quarterly Earnings Growth0.77%N/A
Financial Health
Profit Margin (TTM) i-0.93%0.00%
Operating Margin (TTM) i-0.53%-9.92%
Return on Equity (TTM) i-0.48%1.73%
Debt to Equity (MRQ) i93.67-14.91
Cash & Liquidity
Book Value per Share (MRQ)€1.34€-0.06
Cash per Share (MRQ)€0.83€0.88
Operating Cash Flow (TTM) i€-28,407,456€-91,311,000
Levered Free Cash Flow (TTM) i€-15,377,220€-77,385,752
Dividends
Last 12-Month Dividend Yield iN/AN/A
Last 12-Month Dividend iN/AN/A

Valuation & Enterprise Metrics Analysis: Cellectis S.A vs Inventiva S.A

MetricALCLSIVA
Price Ratios
P/E Ratio (TTM) i-7.41-1.63
Forward P/E i-3.38-3.81
PEG Ratio i-3.38-3.81
Price to Sales (TTM) i4.8143.76
Price to Book (MRQ) i2.26-21.80
Market Capitalization
Market Capitalization i€304.99M€742.58M
Enterprise Value i€213.85M€753.35M
Enterprise Value Metrics
Enterprise to Revenue i3.9644.39
Enterprise to EBITDA i-7.60-7.87
Risk & Other Metrics
Beta i3.070.75
Book Value per Share (MRQ) i€1.34€-0.06

Financial Statements Comparison: Cellectis S.A vs Inventiva S.A

Financial Metrics

Loading Financial Charts...

Revenue

EBITDA

Shareholders Equity

Operating Margin

Free Cash Flow

Long Term Debt

Profit Margin

Current Ratio

Operating Cash Flow

Income Statement (MRQ)

Metric (MRQ)ALCLSIVA
Revenue/Sales i€14.25M€65,000
Cost of Goods Sold i€2.07MN/A
Gross Profit i€12.18MN/A
Research & Development i€19.66M€11.91M
Operating Income (EBIT) i€-8.17M€-13.67M
EBITDA i€-2.02M€-13.43M
Pre-Tax Income i€-20.22M€-14.27M
Income Tax i€0€21,000
Net Income (Profit) i€-20.22M€-14.30M

Balance Sheet & Liquidity Metrics (MRQ)

Metric (MRQ)ALCLSIVA
Cash & Equivalents i€50.95M€122.08M
Total Current Assets i€196.48M€172.81M
Total Current Liabilities i€142.64M€58.46M
Long-Term Debt i€69.71M€51.60M
Total Shareholders Equity i€82.73M€-8.91M
Retained Earnings i€-262.77M€-175.88M
Property, Plant & Equipment i€81.60MN/A

Cash Flow Statement Comparison (MRQ)

Metric (MRQ)ALCLSIVA
Operating Cash Flow i€-16.06M€-24.55M
Capital Expenditures i€-259,829€-63,000
Free Cash Flow i€-9.04M€-12.13M
Debt Repayment i€-3.47M€-1,000
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricALCLSIVA
Shares Short iN/AN/A
Short Ratio iN/AN/A
Short % of Float iN/AN/A
Average Daily Volume (10 Day) i836,406405,098
Average Daily Volume (90 Day) i468,991343,746
Shares Outstanding i61.42M95.66M
Float Shares i41.70M73.51M
% Held by Insiders i0.48%0.08%
% Held by Institutions i0.16%0.69%

Dividend Analysis & Yield Comparison: Cellectis S.A vs Inventiva S.A

MetricALCLSIVA
Last 12-Month Dividend iN/AN/A
Last 12-Month Dividend Yield iN/AN/A
3-Year Avg Annual Dividend iN/AN/A
3-Year Avg Dividend Yield iN/AN/A
3-Year Total Dividends iN/AN/A
Ex-Dividend DateN/AN/A